Kirin (KNBWY)
(Delayed Data from OTC)
$14.95 USD
+0.05 (0.34%)
Updated May 3, 2024 03:59 PM ET
5-Strong Sell of 5 5
D Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KNBWY 14.95 +0.05(0.34%)
Will KNBWY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KNBWY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNBWY
Kirin Holdings Co. (KNBWY) Upgraded to Strong Buy: Here's Why
Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus
KNBWY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Investors Undervaluing Kirin (KNBWY) Right Now?
KNBWY vs. NAPA: Which Stock Is the Better Value Option?
Should Value Investors Buy Kirin (KNBWY) Stock?
Other News for KNBWY
Introducing Bobelo's Postbiotic Immunity with IMMUSE™ for the Whole Family
OLLY Launches New Cognitive Health Supplements With 'Focus Buddies Brainy L'OLLY Pops' Including Cognizin® Citicoline
ENCORE Introduces Innovative Beverage Mixes Featuring Science-Backed Cognizin® and IMMUSE™ for Cognitive and Beauty Support
Warning: KNBWY is at high risk of cutting its dividend
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome